# BrightPath Biotherapeutics

Source: https://onco.cc/companies/brightpath-biotherapeutics/  
OnCo record `brightpath-biotherapeutics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

BrightPath Biotherapeutics is a Japanese company making ready-made immune cell therapies grown from stem cells. Its lead product, BP2202, uses engineered natural killer T cells aimed at the BCMA protein on myeloma cells and is in a first US trial for myeloma that has returned or stopped responding.

## Summary

BrightPath Biotherapeutics Co., Ltd. (Japanese name ブライトパス・バイオ), headquartered in Kojimachi, Chiyoda-ku, Tokyo, with research laboratories at the Life Innovation Center in Kawasaki, was established on 8 May 2003 in Kurume, Fukuoka, according to the company, and listed on the Tokyo Stock Exchange Mothers market in October 2015; it took its present name in July 2017. Earlier work centred on cancer peptide vaccines (ITK-1 in castration-resistant prostate cancer and GRN-1201). Its current platform is iPS-NKT: allogeneic, off-the-shelf natural killer T cells regenerated from a master iPS cell bank. BP2202 is a BCMA-targeted CAR-iNKT cell therapy derived from iPS cells, granted FDA orphan drug designation for multiple myeloma in July 2025; a US open-label, multicentre, dose-escalation phase 1 study in relapsed or refractory multiple myeloma is registered (NCT07667868). The pipeline also lists HER2-targeted CAR-iNKT cells and antibody programmes. Its first registered cancer trial under this sponsor name, NCT07667868, was posted on ClinicalTrials.gov in June 2026.

## Fields

- Kind: Company
- Last checked: 2026-10-29
- Also known as: BrightPath Bio; GreenPeptide
- HQ: Tokyo
- Type: cell-therapy
- Website: https://www.brightpathbio.com/

## Notes

- Read on 29 October 2026: brightpathbio.com Japanese home, company outline (founding date, addresses, history) and BP2202 pages. The English pages returned 404.
- The stock code was not confirmed on the pages read, so no ticker is given. Earlier vaccine trials may have been registered under the former name GreenPeptide; that history was not checked.
-  OnCo has no iPSC-derived NKT technology record, so only the allogeneic cell therapy record is linked.

## Sources

- Official website: https://www.brightpathbio.com/
- BP2202 programme page (Japanese): https://www.brightpathbio.com/pipeline/bp2202.html
- ClinicalTrials.gov: phase 1 trial of BP2202 in relapsed or refractory multiple myeloma (NCT07667868): https://clinicaltrials.gov/study/NCT07667868

## Connected records

- cancers: [Relapsed or refractory multiple myeloma](https://onco.cc/cancers/myeloma-relapsed-refractory/)
- fronts: [Cell Therapy](https://onco.cc/fronts/cell-therapy/), [Immunotherapy](https://onco.cc/fronts/immunotherapy/)
- technologies: [Allogeneic (off-the-shelf) cell therapy](https://onco.cc/technologies/allogeneic-cell-therapy/)
- targets: [BCMA](https://onco.cc/targets/bcma/)

---
JSON: https://onco.cc/api/v1/entities/brightpath-biotherapeutics.json